Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00797563 · ClinicalTrials.gov registry record · NA

Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood

A NA study of Diabetes Mellitus, sponsored by Ascensia Diabetes Care.

Completed
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT00797563 is a NA study of Diabetes Mellitus that has completed, run by Ascensia Diabetes Care. The registered enrollment target is 102 participants, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00797563, a NA study of Diabetes Mellitus, has completed, sponsored by Ascensia Diabetes Care.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study was to evaluate the performance of the meter system in the hands of subjects and healthcare professionals (HCPs). It also evaluated the product user guides in the hands of untrained subjects.

Conditions Studied

Interventions

  • DEVICE Apollo Blood Glucose Monitoring System

Study Locations (1)

New Jersey

  • Consumer Product Testing Co., Inc. - Fairfield

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2008-11
Est. Completion 2008-11
Phase NA

Sponsor

Ascensia Diabetes Care

42 total trials

What the Registry Record Tells You About NCT00797563

The ClinicalTrials.gov registry entry for NCT00797563 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,867-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (95% lower). The listed sponsor is Ascensia Diabetes Care, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 1 intervention - of which Apollo Blood Glucose Monitoring System is the first listed.

NCT00797563 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT00797563 about?

NCT00797563 is a clinical study titled "Evaluation of a New Blood Glucose Meter System With Capillary and Venous Blood". The purpose of the study was to evaluate the performance of the meter system in the hands of subjects and healthcare professionals (HCPs). It also evaluated the product user guides in the hands of untrained subjects.

What is the current status of trial NCT00797563?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2008-11. Estimated completion is 2008-11.

What conditions does trial NCT00797563 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00797563?

The interventions under investigation include: Apollo Blood Glucose Monitoring System (DEVICE).

Who is sponsoring clinical trial NCT00797563?

This trial is sponsored by Ascensia Diabetes Care, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00797563 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.